Sharon S Chen

US Patent:

7141545, Nov 28, 2006

Filed:

Jul 19, 2002

Appl. No.:

10/199449

Inventors:

Marilyn C. Pike - Lincoln MA, US
Grushenka H. I Wolfgang - Oakland CA, US
Sharon A. Chen - Mountain View CA, US
Ralph M. Owen - Petaluma CA, US
Lynn B. Seely - Burlingame CA, US
Hans-Peter Guler - Rye NY, US

Assignee:

Novartis Vaccines and Diagnostics, Inc. - Emeryville CA

International Classification:

A61K 38/16
A61K 38/18

US Classification:

514 12, 514 2

Abstract:

A method for treating mammalian articular cartilage disorders, more particularly osteoarthritis, and trauma-related cartilage injuries using insulin-like growth factor I (IGF-I) is provided. The method comprises increasing the amount of IGF-I at the diseased or injured articular site to a therapeutically effective level that is capable of maintenance and/or regeneration of cartilage, which is beneficial to the long-term treatment of osteoarthritis and trauma-related injuries to cartilage tissues. In one embodiment of the invention, single doses of at least 0. 01 mg of pharmaceutically effective IGF-I are administered intermittently such that the duration of time off of therapy is greater than the time on therapy, more preferably with a frequency of administration of about once per week or less.

US Patent:

20060258588, Nov 16, 2006

Filed:

Jul 17, 2006

Appl. No.:

11/487874

Inventors:

Marilyn Pike - Lincoln MA, US
Grushenka Wolfgang - Oakland CA, US
Sharon Chen - Mountain View CA, US
Ralph Owen - Petaluma CA, US
Lynn Seely - Burlingame CA, US
Hans-Peter Guler - Rye NY, US

Assignee:

Novartis Vaccines and Diagnostics, Inc. - Emeryville CA

International Classification:

A61K 38/18

US Classification:

514012000

Abstract:

A method for treating mammalian articular cartilage disorders, more particularly osteoarthritis, and trauma-related cartilage injuries using insulin-like growth factor I (IGF-I) is provided. The method comprises increasing the amount of IGF-I at the diseased or injured articular site to a therapeutically effective level that is capable of maintenance and/or regeneration of cartilage, which is beneficial to the long-term treatment of osteoarthritis and trauma-related injuries to cartilage tissues. In one embodiment of the invention, single doses of at least 0.01 mg of pharmaceutically effective IGF-I are administered intermittently such that the duration of time off of therapy is greater than the time on therapy, more preferably with a frequency of administration of about once per week or less.

US Patent:

20220267513, Aug 25, 2022

Filed:

Sep 16, 2020

Appl. No.:

17/753415

Inventors:

- Redwood City CA, US
Sharon Chen - Fremont CA, US
Gina Michelle Policastro - San Francisco CA, US
Peyton Hopson - Jacksonville FL, US
Jackie Donners - Pennington NJ, US
Michael Vendely - Cincinnati OH, US
Jason L. Harris - Cincinnati OH, US

International Classification:

C08G 63/08
B33Y 10/00
B33Y 70/00
B33Y 40/20
B29C 64/124
B29C 64/35
C08G 63/91
C08F 290/06
C08K 11/00

Abstract:

Provided herein according to aspects of the present invention are resins that: (a) are suitable for use in additive manufacturing techniques such as bottom-up and top-down stereolithography, (b) produce objects that are bioresorbable, and (c) produce obects that are flexible or elastic (preferably at at least typical room temperatures of 25 C., and in some embodiments at typical human body temperatures of 37 C.). Such resins may include: (a) a bioresorbable polyester oligomer having reactive end groups; (b) non-reactive diluent; (c) optionally reactive diluent; and (d) a photoinitiator.

US Patent:

20230019076, Jan 19, 2023

Filed:

Sep 7, 2022

Appl. No.:

17/930174

Inventors:

- Redwood City CA, US
Sharon Chen - Fremont CA, US
Gina Michelle Policastro - San Francisco CA, US
Peyton Hopson - Jacksonville FL, US
Jackie Donners - Pennington NJ, US
Michael Vendely - Cincinnati OH, US
Jason L. Harris - Cincinnati OH, US

International Classification:

C08G 63/08
B33Y 10/00
B33Y 70/00
B29C 64/124
B29C 64/35
B33Y 40/20
C08F 290/06
C08G 63/91
C08K 11/00

Abstract:

Provided herein according to aspects of the present invention are resins that: (a) are suitable for use in additive manufacturing techniques such as bottom-up and top-down stereolithography, (b) produce objects that are bioresorbable, and (c) produce objects that are flexible or elastic (preferably at at least typical room temperatures of 25 C., and in some embodiments at typical human body temperatures of 37 C.). Such resins may include: (a) a bioresorbable polyester oligomer having reactive end groups; (b) non-reactive diluent; (c) optionally reactive diluent; and (d) a photoinitiator.